Articles tagged with Small Molecule Inhibitors
Muvalaplin, an oral small molecule inhibitor, significantly lowered lipoprotein(a) (Lp[a]) levels in a first-in-human phase 1 study. The treatment showed promise in reducing Lp[a] levels by up to 65% without tolerability concerns.
The Texas Heart Institute has been awarded $1.14 million by the NIH to develop a novel, first-in-class drug for treating atherosclerotic cardiovascular disease. The goal of this research is to target lingering inflammation in patients with cardiovascular disease.
A new antibiotic strategy has been found to defeat gram-negative bacteria like Salmonella and E. coli by interfering with the outer lipid layer of the bacteria. The compound, LPC-233, is a small molecule that works fast and is durable in animal tests, with potentially vital applications against stubborn urinary tract infections.
Researchers developed innovative techniques to treat challenging cancers and manage therapy side effects. Inhibitors targeting PRMT5, a histone-modifying enzyme, alleviated cisplatin-induced hearing loss, while nano-pills delivered combination drugs to liver cancer cells.
Researchers propose targeting non-canonical HH/GLI signaling to improve response rate and durability of therapeutic effects exerted by SMO inhibition in melanoma. The findings suggest that combined targeting of hedgehog signaling and BRD4 could provide a novel therapeutic option against melanoma.
Rice University chemist Han Xiao has won a $3.2 million research grant from the National Cancer Institute to develop an epigenetic inhibitor targeting bone metastasis. The drug, based on existing bisphosphonates, aims to prevent cancer cells from spreading to other organs without affecting normal tissues.
Researchers have identified LP-284 as a novel acylfulvene compound with anti-tumor activity against non-Hodgkin's lymphoma. The compound exerts nanomolar potency in 15 NHL cell lines and prolongs survival of mantle cell lymphoma xenograft mice, making it a potential therapeutic option for patients with HR or TC-NER deficiency.
Scientists at St Jude Children's Research Hospital have captured six cryo-EM structures of a key transporter involved in cancer and immunity, providing unprecedented insight into its function. The findings have significant implications for developing targeted therapies against cancer and autoimmune diseases.
Hollings researchers create small molecule that targets CD38 enzyme activity, stimulating proliferation of natural killer cells and enhancing anti-cancer activity. The compound has potential as an adjuvant therapy to boost effects of existing treatments and reduce resistance to monoclonal antibodies.
BioTCIs, a new class of biomolecular targeted covalent inhibitors, show promise in reducing unwanted side effects. They have semi-permanent drug action and stringent target specificity, making them potential antibody replacements.
Researchers discovered a new approach to treating ependymoma, a rare childhood brain tumor, by targeting YAP fusion proteins. The study found that blocking the function of BRD4 gene expression regulator can prevent tumors from forming.
Researchers discovered that 15-deoxy-prostamide-J2 induces ER stress-mediated apoptosis selectively in tumor cells, reducing melanoma growth. The molecule activates PERK, IP3R, and the mitochondrial permeability transition pore, leading to cell death.
Researchers found that activating the non-mutated form of P53 can change the fundamental makeup of cancer stem cells in mouse models of mucoepidermoid carcinoma. This new therapy approach shows promise for treating this lethal form of salivary gland cancer.
Researchers developed a small molecule inhibitor that successfully shrunk tumors or stopped cancer growth in preclinical models of pancreatic cancer. The drug, MRTX1133, not only targets cancer cells but also cooperates with the immune system to produce a durable response to treatment.
A new review paper discusses the role of CDK4 in regulating the cell cycle and its involvement in cancer. The study highlights the importance of CDK4/6 inhibitors as treatments for ER+ breast cancer and their potential utility in multiple tumor types.
Researchers discovered three essential amino acids - leucine, valine, and tryptophan - as potential metabolic biomarkers for HCC. The study used metabolomics to analyze the differences in tumor and non-tumor tissue metabolomes, revealing striking differences that could aid in diagnosis.
A new chemical probe selectively inhibits human COQ8A in cells, targeting ubiquinone biosynthesis and providing a potential therapeutic strategy for diseases such as cancer. The inhibition of COQ8 has been linked to increased lifespan in certain organisms, suggesting its role in metabolic processes.
Researchers at the University of Illinois Chicago have discovered a small molecule capable of manipulating an immune process that plays a crucial role in cancers and autoimmune diseases. The newly identified enzyme inhibitor could enhance immune responses against tumors, increasing their visibility to T-cells.
Researchers at LSU Health New Orleans have identified a new drug target for triple-negative breast cancer, which lacks estrogen and progesterone receptors. The novel small molecule inhibitor NSC33353 works synergistically with doxorubicin to suppress the growth of TNBC cells.
A new study in The American Journal of Pathology found that inhibiting neuropilin 2 in smooth muscle can enhance contraction and motility of the distal colon. This could provide opportunities to regulate smooth muscle activity in patients with colonic disorders.
Researchers at Nanyang Technological University in Singapore have developed a series of chemical-based compounds that could be potential drug candidates for treating pulmonary tuberculosis. The compounds were licensed by US-based Neuro-Horizon Pharma LLC for commercialization.
Researchers at Michigan Medicine developed a nanoparticle-based inhibitor that successfully triggers the immune system to eliminate brain tumors in mouse models. The approach breaks the shield built by glioma cells around the immune system, allowing the immune cells to attack and delay tumor progression.
A novel inhibitor has been discovered that stalls a critical enzyme inside tumour cells, locking them in place and preventing invasion into healthy tissue. The findings hold promise for the development of metastasis-blocking agents.
A newly discovered small molecule, N-0385, has been found to inhibit entry of the virus into cells, protecting mice from infection prior to exposure and providing effective treatment up to 12 hours after. The treatment holds promise for preventing disease and reducing severity with a few single daily doses.
Researchers develop novel therapeutic approach for treating tuberculosis using phosphatase inhibitors, offering potential benefits for TB research and basic biology exploration. The discovery provides a promising alternative to traditional antibiotic-based treatments and has significant implications for combating antimicrobial resistance.
Cedars-Sinai investigators discover that inhibiting RIPK2 function with drugs or CRISPR/Cas9 reduces prostate cancer metastasis in mice, offering new hope for advanced prostate cancer treatment. Targeting this protein could extend patients' lives by several years.
A UC Riverside-led study has identified a potential antiviral therapy for SARS and SARS-like coronaviruses by targeting the papain-like protease enzyme. The research reveals that subgroup 2b PLpros selectively target specific host immune pathways, making them a promising target for future coronavirus therapeutics.
Researchers have developed a new therapeutic approach to block mutated RAS proteins, which are frequently found in cancers. The method, using small molecules, has the potential to work with multiple mutant forms of RAS in various types of cancers, including pancreatic, lung, and colorectal cancers.
Researchers identified water molecules' impact on protein dynamics and drug target residence time, suggesting that a long target residence time can be important for drug efficacy. This understanding enables more rational drug design in the early stages of drug discovery projects.
A study led by New York University researchers found that the FDA-approved hepatitis C treatment telaprevir can increase bacterial sensitivity to antibiotics and reduce antibiotic resistance. The antiviral blocks the function of essential proteins in bacteria, revealing an opportunity to repurpose the drug to use alongside antibiotics.
Researchers designed novel molecules that bound tightly to SARS-CoV-2's molecular scissors, inhibiting the virus's replication. The breakthrough could lead to new treatments for COVID-19.
Researchers have identified a new potential treatment for neuroblastoma by targeting the ALT mechanism, which is responsible for chemotherapy resistance. The study found that activating ATM kinase at telomeres promotes chemotherapy resistance in ALT neuroblastoma and suggests a cancer-specific approach to treating this disease.
Researchers at the University of Pennsylvania School of Medicine have identified a new mechanism of resistance in advanced chronic lymphocytic leukemia (CLL) patients to CAR T cell therapy. They found that inhibiting the BET protein with the small molecule inhibitor JQ1 can reinvigorate exhausted T cells and increase their production.
Dr. Jitender Mehla has received a National Institutes of Health Grant to study small molecule-based inhibition of multidrug efflux pump in Pseudomonas aeruginosa, a serious threat to hospital-acquired infections. The proposed research aims to develop antibacterials effective against multidrug-resistant Gram-negative pathogens.
The January issue of SLAS Discovery features the cover article 'Cryo-EM: The Resolution Revolution and Drug Discovery', which explores how Cryo-EM is influencing drug discovery projects. The journal also includes 13 articles on original research topics, such as high-throughput screening methods and protein-ligand interactions.
Researchers at Brigham and Women's Hospital developed a small-molecule inhibitor targeting SerpinB9 protein in cancer cells, weakening its defense mechanisms and triggering cell death. The approach shows promise for treating 'cold tumors' that evade immunotherapies.
A research team at Greenwood Genetic Center successfully restored normal heart and valve development in an animal model for Mucolipidosis II using small molecules. The study used cathepsin protease inhibitors to normalize cardiac development in a zebrafish model with genetic mutations that disrupted growth factor signaling.
The October edition of SLAS Discovery features a critical review of mass spectrometry applied to imaging in drug discovery, highlighting its potential for pharmacokinetic and pharmacodynamic measurements. The issue also includes original research articles on various topics in life sciences discovery and technology.
A preclinical study characterized quizartinib's binding affinity and selectivity for FLT3, demonstrating its high affinity and preclinical antitumor activity against midostaurin-resistant AML cells. The study aims to evaluate the role of quizartinib in treating relapsed or refractory AML patients.
Eternygen presents preclinical study data demonstrating INDY inhibition reverses nonalcoholic steatohepatitis (NASH) in a diet-induced mouse model. The treatment also reduces liver injury and inflammation.
Researchers have identified 150 possible inhibitors of the Nipah virus, a highly deadly disease with no licensed drugs against it. The study found that 13 proposed inhibitors showed high potential against all strains of the virus.
A study published in Journal of Alzheimer's Disease shows that a small molecule drug inhibits tau self-association and blocks neurotoxic tau oligomers in an animal model. The compound reduces insoluble tau aggregates and decreases misfolded tau accumulation, demonstrating promising results for treating Alzheimer's disease.
Researchers identified two lead compounds that disrupt SpCas9 DNA binding, enabling precise control over CRISPR-Cas9-based technologies. These small-molecule inhibitors are reversible and dose-dependent, allowing for safe use of gene editing tools.
Researchers have developed a small molecule that effectively treats visceral leishmaniasis in a mouse model, with favorable pharmacokinetic properties and no safety concerns. The compound targets the proteasome, a cellular recycling machine, by binding to a previously undiscovered site.
Researchers have identified two small-molecule experimental inhibitors that target the influenza protein NS1, which plays a crucial role in blocking the body's immune response. The study's findings provide strong evidence for the mechanism of action of these compounds and offer significant structural insights into NS1.
A study on Rett syndrome found that small molecule inhibitors reactivated the inactive X-linked MECP2 gene, rectifying morphological defects in human induced pluripotent stem cell-derived neurons. The treatment has potential therapeutic applications for the neurodevelopmental disorder.
A new methodology for screening small molecule inhibitors against CD73/Ecto-5'-Nucleotidase is presented in SLAS Discovery. The technique uses multiple stable isotope-labeled substrates and ultra-fast RapidFire-MS/MS to identify molecules with diverse inhibition modalities.
Samumed has been selected for seven presentations in five therapeutic areas at the ACR Annual Meeting. The company's novel Wnt pathway inhibitor compounds show potential for treating diseases such as chronic tendinopathy, degenerative disc disease, scleroderma, osteoarthritis, and psoriasis.
Scientists at The Wistar Institute have developed a highly specific telomerase inhibitor that targets the enzyme in approximately 90% of cancers. By binding to a specific pocket on the outer surface of telomerase, the inhibitor prevents the enzyme from properly assembling, leading to cell cycle arrest and senescence.
Researchers found that gene Rb2 inhibits angiogenesis, a critical process for tumor growth. The study suggests that Rb2 may be used to treat lung cancer and glioblastoma by blocking blood vessel formation.
Researchers discovered how a new anticancer drug inhibits a runaway protein switch that causes chronic myelogenous leukemia by exploiting alterations in the shape of the protein. This precise control could give pharmaceutical companies and basic researchers new tools for manipulating cell growth and signaling pathways.
Researchers have developed a new approach to block HIV protease by using small molecules as a 'molecular wedge' to prevent protein interaction. This method may help prevent drug resistance and could be used to treat various diseases, including autoimmune disorders. The study is currently being tested at the National Institutes of Health.
The trial found that eptifibatide significantly reduced deaths and heart attacks by 40% within the first 48 hours of use. This represents a substantial improvement over the current standard treatment, abciximab, which costs $1,500 compared to $400 for eptifibatide.
The report in Science reveals the x-ray crystal structure of MMP-2, a key target for anti-cancer drug candidates. The elucidated structure provides valuable information on the function and regulation of MMP-2, enabling the design of improved inhibitors.
Researchers at HHMI and Stanford University have developed a new method to engineer drug molecules that bind more effectively to their targets. By attaching small molecule inhibitors to larger proteins, the team increased the binding affinity of the inhibitor, making it easier to inhibit protein-protein interactions.